SI1951296T2 - Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom - Google Patents
Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonomInfo
- Publication number
- SI1951296T2 SI1951296T2 SI200630957T SI200630957T SI1951296T2 SI 1951296 T2 SI1951296 T2 SI 1951296T2 SI 200630957 T SI200630957 T SI 200630957T SI 200630957 T SI200630957 T SI 200630957T SI 1951296 T2 SI1951296 T2 SI 1951296T2
- Authority
- SI
- Slovenia
- Prior art keywords
- cell
- dna
- cell culture
- betapropiolactone
- low levels
- Prior art date
Links
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 title 1
- 229960000380 propiolactone Drugs 0.000 title 1
- 229960004854 viral vaccine Drugs 0.000 title 1
- 238000004113 cell culture Methods 0.000 abstract 4
- 229960005486 vaccine Drugs 0.000 abstract 3
- YCHXNMPJFFEIJG-UHFFFAOYSA-N 3-methyloxiran-2-one Chemical compound CC1OC1=O YCHXNMPJFFEIJG-UHFFFAOYSA-N 0.000 abstract 1
- 229940126161 DNA alkylating agent Drugs 0.000 abstract 1
- 239000012624 DNA alkylating agent Substances 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000356 contaminant Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000644 propagated effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73278605P | 2005-11-01 | 2005-11-01 | |
| EP06831855.9A EP1951296B2 (en) | 2005-11-01 | 2006-11-01 | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
| PCT/IB2006/003880 WO2007052163A2 (en) | 2005-11-01 | 2006-11-01 | Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI1951296T1 SI1951296T1 (sl) | 2011-04-29 |
| SI1951296T2 true SI1951296T2 (sl) | 2014-09-30 |
Family
ID=37969762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200630957T SI1951296T2 (sl) | 2005-11-01 | 2006-11-01 | Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom |
Country Status (19)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2301572T3 (pl) * | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
| BR122019013216B8 (pt) | 2006-01-27 | 2021-07-27 | Seqirus Uk Ltd | ensaio imunológico para análise de uma vacina contra influenza |
| EA200970271A1 (ru) | 2006-09-11 | 2010-02-26 | Новартис Аг | Получение вакцин против вируса гриппа без использования куриных эмбрионов |
| ES2393162T3 (es) * | 2007-06-27 | 2012-12-19 | Novartis Ag | Vacunas antigripales con un contenido reducido de aditivos |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| ES2535101T3 (es) | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
| US20110217330A1 (en) * | 2008-11-05 | 2011-09-08 | Bruno Rene Andre | Novel method |
| CN102548577A (zh) | 2009-04-27 | 2012-07-04 | 诺华有限公司 | 用于抵抗流感的佐剂疫苗 |
| ES2394797T3 (es) | 2009-05-21 | 2013-02-05 | Novartis Ag | Genética inversa usando promotores no endógenos de pol l |
| CN104862335A (zh) | 2009-07-31 | 2015-08-26 | 诺华股份有限公司 | 反向遗传系统 |
| WO2011044576A2 (en) | 2009-10-09 | 2011-04-14 | Children's Medical Center Corporation | Selectively disrupted whole-cell vaccine |
| EP2491117B2 (en) | 2009-10-20 | 2017-06-28 | Novartis AG | Improved reverse genetics methods for virus rescue |
| BR112012027643A2 (pt) | 2010-05-03 | 2016-08-16 | Glaxosmithkline Biolog Sa | métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica |
| EA201291179A1 (ru) * | 2010-05-06 | 2013-04-30 | Новартис Аг | Органические пероксидные соединения для инактивации микроорганизмов |
| WO2011145081A1 (en) | 2010-05-21 | 2011-11-24 | Novartis Ag | Influenza virus reassortment method |
| JP5976639B2 (ja) | 2010-06-01 | 2016-08-23 | ノバルティス アーゲー | インフルエンザワクチン抗原の濃縮および凍結乾燥 |
| KR102471356B1 (ko) | 2010-06-01 | 2022-11-28 | 노파르티스 아게 | 동결건조하지 않는 인플루엔자 백신 항원의 농축 |
| CN103052399B (zh) | 2010-08-12 | 2016-06-29 | 依生生物制药控股有限公司 | 用于减少病毒组合物中dna杂质的方法 |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Novartis Ag | Soluble needle arrays for delivery of influenza vaccines |
| JP5999817B2 (ja) * | 2011-02-25 | 2016-10-05 | ノバルティス アーゲー | 外因性の内部陽性対照 |
| MX363409B (es) | 2011-11-03 | 2019-03-20 | Sentinext Therapeutics Sdn Bhd | Antigenos y vacunas dirigidos contra enterovirus hunanos. |
| GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| RU2599496C2 (ru) | 2012-03-06 | 2016-10-10 | Круселл Холланд Б.В. | Улучшенная вакцинация против гриппа |
| US20150161359A1 (en) | 2012-06-04 | 2015-06-11 | Novartis Ag | Methods for safety testing |
| KR20150110494A (ko) | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| BR112015021880A2 (pt) | 2013-03-13 | 2017-09-26 | Novartis Ag | rearranjo de vírus influenza b |
| EP2801372A3 (en) | 2013-05-10 | 2015-02-18 | Novartis AG | Avoiding narcolepsy risk in influenza vaccines |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| US10329537B2 (en) | 2013-06-06 | 2019-06-25 | Seqirus UK Limited | Influenza virus reassortment |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| US10080792B2 (en) | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
| CN104513317B (zh) * | 2013-09-30 | 2018-12-14 | 普莱柯生物工程股份有限公司 | 一种疫苗组合物及其制备方法和应用 |
| WO2015071177A1 (en) | 2013-11-15 | 2015-05-21 | Novartis Ag | Removal of residual cell culture impurities |
| TWI688652B (zh) * | 2014-05-28 | 2020-03-21 | 財團法人國家衛生研究院 | 作為對抗腸病毒感染之免疫原的病毒顆粒及其製造 |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| HUE060924T2 (hu) | 2015-07-07 | 2023-04-28 | Seqirus Uk Ltd | Influenza elleni hatásosság vizsgálata |
| EP3184119A1 (en) * | 2015-12-23 | 2017-06-28 | Themis Bioscience GmbH | Chromatography based purification strategies for measles scaffold based viruses |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| CN109652384B (zh) * | 2019-02-21 | 2021-10-26 | 昆明理工大学 | 一种体外培养戊型肝炎病毒的方法 |
| KR20220098370A (ko) * | 2019-11-07 | 2022-07-12 | 세퀴러스 유케이 리미티드 | 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법 |
| BR112022009545A2 (pt) | 2019-11-18 | 2022-10-11 | Seqirus Pty Ltd | Método para produzir vírus influenza recombinantes |
| WO2022210763A1 (ja) * | 2021-03-30 | 2022-10-06 | デンカ株式会社 | インフルエンザワクチン |
| CN115354071A (zh) * | 2022-08-10 | 2022-11-18 | 上海药明生基医药科技有限公司 | 一种检测重组腺相关病毒宿主细胞dna残留的方法 |
| CN116407624B (zh) * | 2023-04-14 | 2024-04-09 | 吉林省农业科学院(中国农业科技东北创新中心) | 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用 |
| TW202516000A (zh) * | 2023-07-25 | 2025-04-16 | 日商Ｋｍ生物醫藥股份有限公司 | 利用雞蛋培養法進行的去活化流感疫苗的製備方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH589453A5 (cg-RX-API-DMAC7.html) * | 1974-01-14 | 1977-07-15 | Sandoz Ag | |
| US4064232A (en) * | 1974-01-14 | 1977-12-20 | Sandoz Ltd. | Process for isolating the immunogenic components of influenza viruses |
| US4140762A (en) * | 1974-01-14 | 1979-02-20 | Sandoz Ltd. | Influenza sub-unit vaccine |
| JP2661044B2 (ja) | 1986-06-17 | 1997-10-08 | カイロン コーポレイション | 肝炎δの診断薬およびワクチン |
| GB8703696D0 (en) * | 1987-02-18 | 1987-03-25 | Oxford J S | Influenza vaccine |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5010183A (en) | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
| JP2941859B2 (ja) | 1989-09-20 | 1999-08-30 | 国立予防衛生研究所 | Ｈａ蛋白の製造法 |
| US5010112A (en) * | 1989-12-01 | 1991-04-23 | Massachusetts Institute Of Technology | Method and apparatus for improving the insulating properties of closed cell foam |
| US5824536A (en) | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) * | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| ATE285250T1 (de) * | 1998-06-01 | 2005-01-15 | Chiron Corp | Verwendung von polymeren der hyaluronsäure zur mukosalen freigabe von impfstoffen und adjuvantien |
| JP2000230931A (ja) | 1998-12-07 | 2000-08-22 | Katakura Industries Co Ltd | 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| DE60036952T2 (de) | 1999-09-24 | 2008-08-07 | Glaxosmithkline Biologicals S.A. | Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung |
| EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| CA2393469A1 (en) | 1999-12-08 | 2001-06-14 | Crucell Holland B.V. | Method of administering adenovirus |
| AU2001236042B9 (en) | 2000-03-03 | 2006-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| DK1361890T3 (da) | 2001-02-23 | 2011-06-27 | Glaxosmithkline Biolog Sa | Influenzavaccineformuleringer til intradermal indgift |
| GB2386072A (en) | 2001-04-27 | 2003-09-10 | Becton Dickinson Co | Novel vaccine |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| DE10144903A1 (de) | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| CN103540568A (zh) | 2002-04-26 | 2014-01-29 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| EP1590450A2 (en) | 2002-12-20 | 2005-11-02 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
| KR100908757B1 (ko) | 2003-05-28 | 2009-07-22 | 위스콘신 얼럼나이 리서어치 화운데이션 | 백신 및 유전자 요법을 위한 고 역가 재조합 인플루엔자바이러스 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| DE602005015332D1 (de) | 2004-02-23 | 2009-08-20 | Crucell Holland Bv | Verfahren zur Reinigung von Viren |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| NZ551640A (en) | 2004-05-20 | 2010-05-28 | Id Biomedical Corp | Process for the production of an influenza vaccine |
| EP2179744B1 (en) | 2004-09-09 | 2010-12-01 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential latrogenic risks associated with influenza vaccines |
| JP4031478B2 (ja) | 2004-12-13 | 2008-01-09 | プロテイン サイエンシーズ | インフルエンザ血球凝集素多価ワクチンの製造方法 |
| CA2592120A1 (en) | 2004-12-23 | 2006-07-06 | Medimmune Vaccines, Inc. | Non-tumorigenic mdck cell line for propagating viruses |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| PL2301572T3 (pl) * | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
| KR20140075022A (ko) * | 2006-09-15 | 2014-06-18 | 메디뮨 엘엘씨 | 높은 역가로 바이러스 증식을 지원하는 ｍｄｃｋ 세포주 및 이를 이용한 생물반응기 공정 |
-
2006
- 2006-11-01 PL PL10075529T patent/PL2301572T3/pl unknown
- 2006-11-01 EA EA200801221A patent/EA014062B1/ru not_active IP Right Cessation
- 2006-11-01 WO PCT/IB2006/003880 patent/WO2007052163A2/en not_active Ceased
- 2006-11-01 CN CN201410631136.2A patent/CN104474543A/zh active Pending
- 2006-11-01 AT AT06831855T patent/ATE494906T1/de active
- 2006-11-01 JP JP2008538454A patent/JP5602366B2/ja active Active
- 2006-11-01 DK DK06831855.9T patent/DK1951296T4/da active
- 2006-11-01 SI SI200630957T patent/SI1951296T2/sl unknown
- 2006-11-01 EP EP10075529.7A patent/EP2301572B1/en not_active Revoked
- 2006-11-01 EP EP14183359.0A patent/EP2842572A1/en not_active Ceased
- 2006-11-01 EP EP06831855.9A patent/EP1951296B2/en active Active
- 2006-11-01 NZ NZ567817A patent/NZ567817A/en not_active IP Right Cessation
- 2006-11-01 CN CN200680046034.8A patent/CN101365480B/zh not_active Expired - Fee Related
- 2006-11-01 US US12/092,190 patent/US10655108B2/en active Active
- 2006-11-01 ES ES06831855.9T patent/ES2359214T5/es active Active
- 2006-11-01 ES ES10075529.7T patent/ES2525518T3/es active Active
- 2006-11-01 AU AU2006310171A patent/AU2006310171B2/en active Active
- 2006-11-01 DE DE602006019629T patent/DE602006019629D1/de active Active
- 2006-11-01 PT PT100755297T patent/PT2301572E/pt unknown
- 2006-11-01 CA CA002627971A patent/CA2627971A1/en not_active Abandoned
- 2006-11-01 KR KR1020087013164A patent/KR20080081254A/ko not_active Ceased
- 2006-11-01 PL PL06831855T patent/PL1951296T5/pl unknown
-
2011
- 2011-04-05 CY CY20111100356T patent/CY1111378T1/el unknown
- 2011-04-29 AU AU2011201968A patent/AU2011201968B2/en active Active
- 2011-09-21 JP JP2011206634A patent/JP2011256209A/ja not_active Withdrawn
-
2014
- 2014-07-23 JP JP2014149517A patent/JP6639077B2/ja active Active
-
2015
- 2015-09-01 HK HK15108523.2A patent/HK1207828A1/en unknown
-
2016
- 2016-07-25 JP JP2016145286A patent/JP7049761B2/ja active Active
-
2019
- 2019-10-23 JP JP2019192740A patent/JP2020023557A/ja active Pending
-
2020
- 2020-04-09 US US16/843,940 patent/US11466257B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1951296T2 (sl) | Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| WO2007024941A3 (en) | Polyvalent vaccine | |
| BR112013011194A2 (pt) | partículas de glicoproteína semelhantes a vírus (vlps) da raiva. | |
| WO2010019262A3 (en) | Polyvalent vaccine | |
| MX2012000035A (es) | Antigenos de virus de sincicio respiratorio recombinantes. | |
| PH12013502621A1 (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
| WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
| MY151062A (en) | Pseudoinfectious flavivirus and uses thereof | |
| WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
| WO2009026465A3 (en) | Composition and methods of making and using influenza proteins | |
| WO2010001409A3 (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
| WO2007117303A3 (en) | Combination vaccine comprising an attenuated bovine viral diarrhea virus | |
| WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
| EA201170533A1 (ru) | Высокодиспергируемый диоксид кремния для резин и способ его получения | |
| WO2009009759A3 (en) | Yersinia pestis antigens, vaccine compositions, and related methods | |
| WO2008048344A3 (en) | Bacillus anthracis antigens, vaccine compositions, and related methods | |
| WO2007002470A3 (en) | Inactivated chimeric vaccines and related methods of use | |
| PH12015501378A1 (en) | Porcine parvovirus 5a, methods of use and vaccine | |
| MX2010006984A (es) | Vacunas contra la malaria. | |
| WO2008115314A3 (en) | Flavivirus vaccine vector against influenza virus | |
| AU2017261706A1 (en) | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | |
| WO2007082734A3 (en) | Influenza vaccine | |
| PL1796717T3 (pl) | Szczepionka skojarzona | |
| DE60325838D1 (de) | Imidazoquinolinamine als adjuvantien für hiv dna vakzine |